Dynamic Technology Lab Private Ltd Lowers Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL)

Dynamic Technology Lab Private Ltd trimmed its stake in Castle Biosciences, Inc. (NASDAQ:CSTL) by 59.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 17,630 shares of the company’s stock after selling 26,264 shares during the quarter. Dynamic Technology Lab Private Ltd’s holdings in Castle Biosciences were worth $470,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of CSTL. Wells Fargo & Company MN boosted its stake in Castle Biosciences by 29.0% in the 4th quarter. Wells Fargo & Company MN now owns 15,375 shares of the company’s stock worth $410,000 after purchasing an additional 3,460 shares in the last quarter. Trexquant Investment LP raised its holdings in Castle Biosciences by 27.5% in the fourth quarter. Trexquant Investment LP now owns 203,571 shares of the company’s stock worth $5,425,000 after buying an additional 43,947 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Castle Biosciences by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 628,196 shares of the company’s stock worth $16,746,000 after buying an additional 3,513 shares in the last quarter. Franklin Resources Inc. lifted its stake in shares of Castle Biosciences by 6.1% in the fourth quarter. Franklin Resources Inc. now owns 73,637 shares of the company’s stock worth $1,962,000 after buying an additional 4,255 shares in the last quarter. Finally, Wellington Management Group LLP purchased a new stake in shares of Castle Biosciences during the fourth quarter valued at approximately $19,244,000. 92.60% of the stock is owned by hedge funds and other institutional investors.

Castle Biosciences Price Performance

NASDAQ CSTL opened at $18.60 on Wednesday. The stock has a market capitalization of $536.41 million, a price-to-earnings ratio of 93.00 and a beta of 1.11. Castle Biosciences, Inc. has a 1-year low of $16.97 and a 1-year high of $35.84. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.78 and a quick ratio of 7.64. The business’s fifty day moving average price is $23.03 and its 200-day moving average price is $27.35.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Guggenheim set a $30.00 price objective on shares of Castle Biosciences and gave the stock a “buy” rating in a report on Friday, March 28th. Stephens restated an “overweight” rating and issued a $41.00 price target on shares of Castle Biosciences in a research note on Thursday, January 2nd. Finally, Robert W. Baird increased their price objective on Castle Biosciences from $36.00 to $37.00 and gave the company an “outperform” rating in a research report on Friday, February 28th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, Castle Biosciences has an average rating of “Buy” and a consensus target price of $38.75.

Insider Buying and Selling at Castle Biosciences

In other Castle Biosciences news, insider Derek J. Maetzold sold 22,639 shares of the company’s stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $20.12, for a total transaction of $455,496.68. Following the completion of the sale, the insider now directly owns 80,465 shares of the company’s stock, valued at approximately $1,618,955.80. This represents a 21.96 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Daniel Bradbury sold 7,867 shares of the stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $28.17, for a total transaction of $221,613.39. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 34,858 shares of company stock valued at $771,416. 7.20% of the stock is owned by company insiders.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.